ストックスクリーナーアプリを入手
3.46
6.49%
-0.24
アフターアワーズ：
3.60
0.14
+4.05%
Anixa Biosciences Inc (ANIX) 最新ニュース
Anixa Biosciences (ANIX) CEO purchases 3,188 shares at $3.37 each - Stock Titan
Form 4 Anixa Biosciences Inc For: 27 July By Investing.com - Investing.com Canada
Anixa Biosciences CEO Amit Kumar buys $11,190 in company stock By Investing.com - Investing.com Canada
Anixa Biosciences CEO Amit Kumar buys $11,190 in company stock - Investing.com
Anixa Biosciences Inc (ANIX) CEO purchases 3,000 shares at $3.73 - Stock Titan
Anixa Biosciences, Inc. Revenue Breakdown – NASDAQ:ANIX - TradingView
Anixa Biosciences Inc (ANIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ANIX|Anixa Biosciences Inc|Price:3.700|Chg%:-0.050 - TradingKey
TradingKey - TradingKey
ANIX|Anixa Biosciences Inc|Price:3.725|Chg%:+0.025 - TradingKey
ANIX|Anixa Biosciences Inc|Price:3.680|Chg%:-0.020 - TradingKey
Anixa Biosciences Inc (ANIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anixa Biosciences Inc (ANIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance UK
New Strong Buy Stocks for July 22nd - The Globe and Mail
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc - GuruFocus
3 Penny Stocks With Market Caps Over $100M To Consider - Sahm
Anixa Biosciences (ANIX) CEO buys 5,000 common shares - Stock Titan
Anixa Biosciences Inc. (ANIX) Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline Advances - dars.gov.et
Insider Buying: Titterton Lewis H Jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX) - GuruFocus
Anixa Biosciences CEO Amit Kumar acquires 5,000 common shares for $17,300 - Bitget
Anixa Biosciences (ANIX) director purchases 12,000 shares of common stock - Stock Titan
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance - AOL.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Anixa Biosciences Director Lewis H. Titterton Jr acquires $9,172 of common shares - Bitget
Anixa Biosciences director buys $9,174 in common stock By Investing.com - Investing.com South Africa
Insider Buying: Titterton Lewis H Jr Increases Stake in Anixa Bi - GuruFocus
Anixa Biosciences director buys $9,174 in common stock - Investing.com
Form 4 Anixa Biosciences Inc For: 16 July By Investing.com - Investing.com Canada
Director Lewis Titterton buys more Anixa Biosciences Inc (ANIX) stock - Stock Titan
Anixa Biosciences (ANIX) Secures New Patent for Breast Cancer Va - GuruFocus
Anixa Biosciences Secures Patent Approval in Australia for Breas - GuruFocus
Anixa Biosciences (ANIX) Secures New Patent for Breast Cancer Vaccine Technology - GuruFocus
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology - PR Newswire
Anixa Biosciences (ANIX) Faces Modest Decline, Testing Key Support at $2.89Percent Above MA - dars.gov.et
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc with Rec - GuruFocus
Form 4 Anixa Biosciences Inc For: 13 July By Investing.com - Investing.com Nigeria
Anixa Biosciences CEO Amit Kumar buys $15,200 in stock By Investing.com - Investing.com Canada
Anixa Biosciences (ANIX) CEO Amit Kumar buys 5,000 shares at $3.04 - Stock Titan
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Trial to Highest Dose Cohort - HLTH
Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial - Moomoo
Anixa doses first patient in highest cohort of ovarian trial By Investing.com - Investing.com South Africa
Anixa doses first patient in highest cohort of ovarian trial - Investing.com
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level. - Bitget
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date - PR Newswire
ANIXAnixa Biosciences Inc Revenue Breakdown - Finviz
D. Boral Capital Initiates Anixa Biosciences(ANIX.US) With Buy Rating, Announces Target Price $10 - Moomoo
Here's why you should add ANIX stock to your portfolio now - MSN
ANIX Assumed by D. Boral Capital -- Rating Maintained at Buy - GuruFocus
Anixa Biosciences Price Target Maintained With a $10.00/Share by D. Boral Capital - Moomoo
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 - AOL.com
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):